Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial

Pharmaceutical Executive Daily: Ultragenyx's Apazunersen Fails Phase III Trial

Published 2 months, 2 weeks ago
Description
Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linked real-world data sets, and Melanie Whittington joins The Ron Lanton Report to argue biopharma policy needs to stay tethered to patients, not abstractions.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us